期刊文献+

莫西沙星注射液治疗呼吸道细菌性感染的临床研究 被引量:1

Clinical study of Moxifloxacin injection in treatment of bacterial infections of respiratory tract
下载PDF
导出
摘要 目的观察莫西沙星注射液治疗呼吸道细菌性感染的临床疗效与安全性。方法将60例呼吸道细菌性感染患者随机分为治疗组和对照组各30例。治疗组给予莫西沙星注射液静脉滴注;对照组给予左氧氟沙星注射液静脉滴注,疗程均为7~14d。结果治疗组临床总有效率为93.3%,高于对照组的76.7%;细菌清除率为92.0%,高于对照组的80.8%,差异均有统计学意义(P<0.05)。治疗组和对照组不良反应发生率分别为13.3%、16.7%,差异无统计学意义(P>0.05)。结论莫西沙星注射液治疗呼吸道细菌性感染疗效显著,值得临床推广应用。 Objective To evaluate the efficacy and safety of moxifloxacin injection in the treatment of respiratory tract bacterial infections.Methods A total of 60 patients were randomly divided into treatment group and control group(30 in each).The treatment group was treated with moxifloxacin injection,the control group was treated with levofloxacin injection both groups were treated for 7~14d.Results The total clinical effective rate was 93.3%in treatment group and 76.7% in control group(P0.05).The bacterial eradication rate in treatment group and in control group were 92.0% and 80.8% respectively(P0.05).There was significant difference between two group in the clinical efficacy.The incidence rate of adverse reactions was 13.3% in the treatment group and 16.7% in the control group(P0.05).Conclusion Moxifloxacin injection is an effective and safe antibiotics for the treatment of respiratory tract bacterial infections.
作者 李永法
出处 《临床合理用药杂志》 2012年第11期15-16,共2页 Chinese Journal of Clinical Rational Drug Use
关键词 莫西沙星 左氧氟沙星 感染 细菌性 呼吸道 疗效 Moxifloxacin Levofloxacin Infection bacterial respiratory tract Curative effect
  • 相关文献

参考文献4

二级参考文献23

  • 1陈立军,江荣林,毛文炜,邵海燕,周仁芳,陈军.莫西沙星治疗106例社区获得性肺炎病人的前瞻性研究[J].中国新药与临床杂志,2005,24(1):14-17. 被引量:30
  • 2李仲兴,王秀华,孟晓洁,杨敬芳,时冬艳,王鑫.莫西沙星对224株肠球菌的体外抗菌活性研究[J].中国抗生素杂志,2005,30(7):412-415. 被引量:12
  • 3社区获得性肺炎诊断和治疗指南[J].中华结核和呼吸杂志,2006,29(10):651-655. 被引量:3062
  • 4MIRAVITLLES M, MOLINA J, BROSA M. Clinical efficacy of moxifloxacin in the treatment of exacerbations of chronic bronchitis: a systematic review and metaanalysis[J]. Arch Bronconeumol, 2007, 43(1 ): 22-28. 被引量:1
  • 5FERRARA AM. A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia(CAP)[J]. Clin Interv Aging, 2007, 2(2) : 179-187. 被引量:1
  • 6MIRAVITLLES M. Moxifloxacin in the management of exacerbations of chronic bronchitis and COPD [J]. Int J Chron Obstruct Pulmon Dis, 2007, 2(3): 191-204. 被引量:1
  • 7HOFFKEN G, BARTH J, RUBINSTEIN E, et al A randomized study of sequential intravenous/oral moxifloxacin in comparison to sequential intravenous ceftriaxone/oral cefuroxime axetil in patients with hospital-acquired pneumonia [J]. Infection, 2007, 35(6) : 414-420. 被引量:1
  • 8TORRES A, GARAU J, ARVIS P, etal. Moxifloxacin monotherapy is effective in hospitalized patients with community-acquired pneumonia: the MOTIV study a randomized clinical trial[J]. Clin Infect Dis, 2008, 46(10) : 1499-1509. 被引量:1
  • 9STARAKIS I, GOGOS CA, BASSARIS H. Five-day moxifloxacin therapy compared with 7-day co-amoxiclav therapy for the treatment of acute exacerbation of chronic bronchitis [J]. Int Antimicrob Agents, 2004, 23(2): 129-137. 被引量:1
  • 10KOCH H, LANDEN H, STAUCH K. Once-daily moxifloxacin therapy for community-acquired pneumonia in general practice: evidence from a post-marketing surveillance study of 1467 patients [J]. Clin Drug Investig, 2004, 24(8) : 441-448. 被引量:1

共引文献39

同被引文献5

引证文献1

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部